Abstract
In rats a maximal tolerated dose of carboplatin (60 mg kg-1, i.v.) caused severe anaemia, leucopenia and thrombocytopenia. These indices of haematological toxicity were also observed with a maximal tolerated dose of cis-platin (6.5 mg kg-1, i.v.), but reductions in blood cell counts were less than those observed with carboplatin. Anaemia was deduced to be the dose-limiting toxicity of carboplatin, since red cell transfusions afforded protection to rats receiving a lethal dose of this compound (80 mg kg-1, i.v.). Anaemia did not appear to be due to an increase in the susceptibility of cis-platin- or carboplatin-exposed red cells to lysis, as concluded from results of osmotic fragility tests. These red cells, when tagged with 51Cr, also did not exhibit reductions in survival time. Administration of 51Cr-labelled control red cells to rats, which had been treated with carboplatin 3 days earlier, resulted in substantial loss of the radiolabel from the circulation, indicating that internal haemorrhaging, as a result of thrombocytopenia, is probably the principle cause of drug-induced anaemia.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BELCHER E. H., HARRISS E. B. Studies of red cell life span in the rat. J Physiol. 1959 May 19;146(2):217–234. doi: 10.1113/jphysiol.1959.sp006190. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Calvert A. H., Harland S. J., Newell D. R., Siddik Z. H., Jones A. C., McElwain T. J., Raju S., Wiltshaw E., Smith I. E., Baker J. M. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol. 1982;9(3):140–147. doi: 10.1007/BF00257742. [DOI] [PubMed] [Google Scholar]
- Crocker C. L. Rapid determination of urea nitrogen in serum or plasma without deproteinization. Am J Med Technol. 1967 Sep-Oct;33(5):361–365. [PubMed] [Google Scholar]
- Getaz E. P., Beckley S., Fitzpatrick J., Dozier A. Cisplatin-induced hemolysis. N Engl J Med. 1980 Feb 7;302(6):334–335. doi: 10.1056/NEJM198002073020607. [DOI] [PubMed] [Google Scholar]
- Levine B. S., Henry M. C., Port C. D., Richter W. R., Urbanek M. A. Nephrotoxic potential of cis-diamminedichloroplatinum and four analogs in male Fischer 344 rats. J Natl Cancer Inst. 1981 Jul;67(1):201–206. [PubMed] [Google Scholar]
- Nguyen B. V., Jaffe N., Lichtiger B. Cisplatin-induced anemia. Cancer Treat Rep. 1981 Nov-Dec;65(11-12):1121–1121. [PubMed] [Google Scholar]
- Nowrousian M. R., Schmidt C. G. Effects of cisplatin on different haemopoietic progenitor cells in mice. Br J Cancer. 1982 Sep;46(3):397–402. doi: 10.1038/bjc.1982.216. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ottaway J. H. Normalization in the fitting of data by iterative methods. Application to tracer kinetics and enzyme kinetics. Biochem J. 1973 Jul;134(3):729–736. doi: 10.1042/bj1340729. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Prestayko A. W., D'Aoust J. C., Issell B. F., Crooke S. T. Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev. 1979 Mar;6(1):17–39. doi: 10.1016/s0305-7372(79)80057-2. [DOI] [PubMed] [Google Scholar]
- Von Hoff D. D., Rozencweig M. cis-Diamminedichloroplatinum(II): a metal complex with significant anticancer activity. Adv Pharmacol Chemother. 1979;16:273–298. doi: 10.1016/s1054-3589(08)60247-1. [DOI] [PubMed] [Google Scholar]
- Wiltshaw E., Evans B. D., Jones A. C., Baker J. W., Calvert A. H. JMS, successor to cisplatin in advanced ovarian carcinoma? Lancet. 1983 Mar 12;1(8324):587–587. doi: 10.1016/s0140-6736(83)92834-9. [DOI] [PubMed] [Google Scholar]